Jie Zhu

Prof. Jie Zhu

Sichuan Cancer Hospital, Chengdu, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in International Journal of Surgery
Verified
Journal Article
Open access
JZJie Zhu
Jie Zhu
YWYi Wang
Yi Wang
HSHongfu Sun
Hongfu Sun
YZYaowen ZHANG
Yaowen ZHANG
WZWencheng Zhang
Wencheng Zhang
ZLZhongxing Liao
Zhongxing Liao
Background: There is no standard management for small cell esophageal carcinoma (SCEC). The purpose of this multicenter, retrospective study (ChiSCER) was to investigate the treatment, outcomes, and risk factors impacting survival endpoints in patients with limited-stage SCEC (LS-SCEC). Materials and Methods: Consecutive patients with LS-SCEC from 14 institutions between 2000 and 2020 in China were enrolled. Survival curves were constructed using the Kaplan–Meier method and compared using a log-rank test. Univariate and multivariate Cox regression models and propensity score matching (PSM) analysis were adopted in the prognostic analysis. Results were reported as hazard ratio (HR), 95% confidence interval (CI), and P value. Statistical significance was set as P value <0.05 in a two-tailed test. Results: Among 458 LS-SCEC patients, the median age was 63 [interquartile range (IQR), 57–68] years, and 318 (69%) were males. Eighty-four (18%), 167 (36%), and 207 (45%) patients received chemotherapy (CT) alone, CT plus definitive radiotherapy (CT+RT), and CT plus radical surgery (CT+S), respectively. With a median follow-up time of 58.7 (95% CI 48.9–68.6) months, the median overall survival (OS) and 3-year OS rate for all patients 24.3 (95% CI 21.6–27) months and 37.3% (95% CI 32.8–42.5%), respectively. Multivariate analysis indicated that treatment modes, Karnofsky performance status (KPS), TNM stage, and CT cycle were independent prognostic factors for OS (P0.05). Subgroup analysis indicated that compared with CT+RT, patients with tumor location at lower 1/3 (HR 0.59, 95% CI 0.37–0.93, P=0.03) or tumor length >5 cm (HR 0.52, 95% CI 0.3–0.9, P=0.02) could obtain significant OS benefit from CT+S. Patients with tumor location at middle 1/3 (HR 1.55, 95% CI 1.03–2.36, P=0.04) or tumor length ≤5 cm (HR 1.49, 95% CI 1.02–2.17, P=0.04) favored CT+RT. Distant metastasis accounted for 73.7% of all treatment failures after multidisciplinary treatments. Conclusion: Surgery and RT were equally effective local therapies for patients with LS-SCEC. The personalized decision of local therapy should be made after comprehensive considerations on tumor location, length, comorbidities, and organ preservation.

13 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JZJie Zhu
Jie Zhu
YHYongtao Han
Yongtao Han
WNWenjie Ni
Wenjie Ni
XCXiao Chang
Xiao Chang
LWLei Wu
Lei Wu
LPLin Peng
Lin Peng
Background and purpose: The aim of this study is to develop a prognostic nomogram, quantify survival benefit, and guide risk-dependent adjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) after esophagectomy. Materials and methods: This was a single-center, retrospective study of consecutive LA-ESCCs treated by curative-intent esophagectomy with internal validation and independent external validation in a randomized controlled trial. After factor selection by the least absolute shrinkage and selection operator regression, a nomogram was developed to estimate 5-year overall survival (OS) based on the Cox proportional hazards model. The area under the curve (AUC) and calibration plot were used to determine its discriminative and predictive capacities, respectively. Survival improvement from adjuvant therapy was quantified and plotted corresponding to nomogram score. Results: A total of 1077, 718, and 118 patients were included for model development, internal validation, and external validation, respectively. The nomogram identified eight significant prognostic factors: gender, pathological T and N stages, differentiation, surgical margin, lymphovascular invasion, number of lymph node resection, and adjuvant therapy. The nomogram showed superior discriminative capacity than TNM stage (AUC: 0.76 vs. 0.72, p < 0.01), with significant survival differences among different risk stratifications. The calibration plot illustrated a good agreement between nomogram-predicated and actual 5-year OS. Consistent results were concluded after external validation. At least 10% 5-year OS improvement from adjuvant chemoradiotherapy and chemotherapy was expected in almost all patients (nomogram score 110 to 260) and patients mainly with high-intermediate risk (nomogram score 159 to 207), respectively. Conclusions: The clinicopathological nomogram predicting 5-year OS for LA-ESCC after esophagectomy was developed with high accuracy. The proposed nomogram showed better performance than TNM stage and provided risk-dependent and individualized adjuvant treatment recommendations.

18 February 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JLJingqiu Li
Jingqiu Li
XZXiaoding Zhou
Xiaoding Zhou
LWLei Wu
Lei Wu
JMJiabao Ma
Jiabao Ma
YTYan Tan
Yan Tan
QSQiuling Shi
Qiuling Shi
The administration of second-line or subsequent immune checkpoint inhibitors (ICIs) in previously treated patients with advanced solid cancers has been clinically investigated. However, previous clinical trials lacked an appropriate primary endpoint for efficacy assessment. This systematic review aimed to explore the most optimal early efficacy endpoint for such trials. Phase 2 or 3 clinical trials involving patients with advanced solid cancers with disease progression following standard first-line therapy receiving second-line or subsequent ICI administration, with adequate survival outcome data, were included from PubMed, Embase, Web of Science, and Cochrane Library databases before February 2023. Quality assessment was conducted using the Cochrane tool and Newcastle–Ottawa Quality Assessment Scale for Cohort Studies for randomized controlled trials (RCTs) and non-randomized trials, respectively. Objective response rate (ORR) and progression-free survival (PFS) at 3, 6, and 9 months were investigated as potential early efficacy endpoint candidates for 12-month overall survival (OS), with a strong correlation defined as Pearson’s correlation coefficient r ≥ 0.8. A total of 64 RCTs comprising 22,725 patients and 106 non-randomized prospective trials involving 10,608 participants were eligible for modeling and external validation, respectively. RCTs examined 15 different cancer types, predominantly non-small-cell lung cancer (NSCLC) (17, 28%), melanoma (9, 14%), and esophageal squamous cell carcinoma (5, 8%). The median sample size of RCTs was 124 patients, and the median follow-up time was 3.2–57.7 months. The ORR (r = 0.38; 95% confidence interval [CI], 0.18–0.54) and PFS (r = 0.42; 95% CI, 0.14–0.64) exhibited weak trial-level correlations with OS. Within ICI treatment arms, the r values of ORR and 3-, 6-, and 9-month PFS with 12-month OS were 0.61 (95% CI, 0.37–0.79), 0.78 (95% CI, 0.62–0.88), 0.84 (95% CI, 0.77–0.90), and 0.86 (95% CI, 0.79–0.90), respectively. External validation of 6-month PFS indicated an acceptable discrepancy between actual and predicted 12-month OS. In non-randomized phase 2 trials on second-line or subsequent ICI therapy in patients with advanced solid cancers, 6-month PFS could serve as an early efficacy endpoint. However, early efficacy endpoints are not recommended in RCTs to replace OS.

28 October 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RLRanxi Liang
Ranxi Liang
QPQian Peng
Qian Peng
GYGaoshu Yan
Gaoshu Yan
JMJiabao Ma
Jiabao Ma
DHDandan Huang
Dandan Huang
JZJie Zhu
Jie Zhu
The application of guidance template in interstitial brachytherapy (ISBT) was expected to improve target coverage and sparing organs at risk for locally ad

25 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JZJie Zhu
Jie Zhu
HLHaoshen Li
Haoshen Li
JLJianchao Lu
Jianchao Lu
JCJunqiang Chen
Junqiang Chen
LPLijun Peng
Lijun Peng
QWQifeng Wang
Qifeng Wang
Background: Manual assessment of lymph node metastasis (LNM) in esophageal squamous cell carcinoma (ESCC) is inconsistent, and this study is aimed to develop a deep learning tool, DeepLNM, for LNM identification in ESCC. Methods: Consecutive ESCC patients with radical esophagectomy at Sichuan Cancer Hospital (2009–2018) comprised the internal cohort to develop DeepLNM, with three independent external test sets. Regional lymph nodes (LNs) with nodal stations were automatically segmented on computed tomography (CT) scans, and manually annotated according to histopathology. The DeepLNM diagnostic performance was evaluated by the area under the receiver operating characteristic curve (AUC) with its 95% confidence interval (CI), and compared to physicians. Findings: The internal set comprised 815 ESCC patients (2,631 LN masks) for DeepLNM development, with 657 patients (4,314 annotations) in the external set. DeepLNM achieved an AUC of 0.92 (95% CI: 0.90, 0.94) for lesion-level LNM identification in the internal dataset with the most optimal sensitivity 0.85 and specificity 0.86, and AUCs of 0.89 (95% CI: 0.86, 0.92), 0.90 (95% CI: 0.86, 0.93), and 0.89 (95% CI: 0.86, 0.91) in the external test set 1, 2, and 3, respectively. For patient-level N-stage classification, DeepLNM demonstrated an AUC of 0.86 (95% CI: 0.84, 0.89) in the internal dataset with the most optimal sensitivity 0.73 and specificity 0.85, and AUCs of 0.84 (95% CI: 0.79, 0.88), 0.85 (95% CI: 0.77, 0.92), and 0.81 (95% CI: 0.75, 0.86) in the external test set 1, 2, and 3, respectively. DeepLNM outperformed oncologists in AUCs of LNM identification (0.91 vs 0.66–0.78, P < 0.05) and N-stage classification (0.83 vs 0.53–0.67, P < 0.05). Interpretation: DeepLNM accurately detected LNM and classified N-stage in patients with ESCC using pretreatment CT, highlighting its clinical value in personalized risk stratification and risk-adapted treatment.

27 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JZJie Zhu
Jie Zhu
HLHaoshen Li
Haoshen Li
JLJianchao Lu
Jianchao Lu
JCJunqiang Chen
Junqiang Chen
YWYirui Wang
Yirui Wang
QWQifeng Wang
Qifeng Wang
Background: Accurate preoperative lymph node metastasis (LNM) assessment on computed tomography (CT) in esophageal squamous cell carcinoma (ESCC) remains challenging. The aim of this study is to develop and validate an artificial intelligence (AI) tool NODAL-MAP for preoperative LNM identification in ESCC using a multicenter dataset. Methods: The NODAL-MAP was developed using a retrospective internal cohort of consecutive ESCC patients undergoing upfront radical esophagectomy at Sichuan Cancer Hospital (2009–2018), and externally validated across three independent cohorts. Regional lymph nodes (LNs) with nodal stations were automatically segmented on contrast-enhanced chest CT scans, with metastasis status manually annotated based on histopathology. NODAL-MAP’s diagnostic performance was primarily evaluated using the area under the receiver operating characteristic curve (AUC) and its 95% confidence interval (CI), and further compared against four board-certified oncologists. Statistical significance was defined as a two-sided P < 0.05. Findings: NODAL-MAP was developed using 2,631 LN masks (188 metastatic, 7.1%) from 815 ESCC patients, and externally validated on 4,314 LN masks from 657 patients. NODAL-MAP achieved an AUC of 0.92 (95% CI: 0.90, 0.94) for lesion-level LNM identification in the internal dataset under five-fold cross-validation with the most optimal sensitivity 0.85 and specificity 0.86, and AUCs of 0.89 (95% CI: 0.86, 0.92), 0.90 (95% CI: 0.86, 0.93), and 0.89 (95% CI: 0.86, 0.91) in the external test set 1, 2, and 3, respectively. For patient-level nodal staging (N0 vs N+), NODAL-MAP demonstrated an AUC of 0.86 (95% CI: 0.84, 0.89) in the internal dataset with the most optimal sensitivity 0.73 and specificity 0.85, and AUCs of 0.84 (95% CI: 0.79, 0.88), 0.85 (95% CI: 0.77, 0.92), and 0.81 (95% CI: 0.75, 0.86) in the external test set 1, 2, and 3, respectively. NODAL-MAP significantly outperformed the four experienced oncologists in LNM identification (AUC 0.91 vs 0.66–0.78, P < 0.05) and N-stage classification (AUC 0.83 vs 0.53–0.67, P < 0.05) in reader study. Interpretation: AI-based NODAL-MAP model identifying LNM in ESCC accurately was successfully developed with rigorous validations. NODAL-MAP could serve as a valuable AI tool for the precise mapping of metastatic LNs in ESCC.